Public Calls for Stricter Ova Regulation
By The Korea Times,
The Korea Times
| 01. 12. 2006
Voices are getting louder over the revision of the bioethics law amid allegations that female researchers of Prof. Hwang Woo-suk's team were forced to donate their ova for stem cell experiments.
Prof. Chung Myung-hee, head of the Seoul National University (SNU) panel investigating Hwang's fabrication of research data, announced Tuesday that a total of 2,061 eggs from 129 females were collected from four hospitals and provided to his team for three years from November 2002.
The key question is whether Hwang's team has violated the bioethics law that took effect in January last year.
The law forbids the trade of sperm and ova for commercial purposes. It stipulates that those offering ovum for a commercial purpose are subject to prison terms of up to three years and those arranging the illegal trade may face imprisonment of up to two years.
In short, if egg-donation takes place voluntarily without commercial benefits, it is not punishable. In addition, those who were involved even in commercial ova trading that took place before 2005 are not subject to any punishment.
Cloning scientist Hwang admitted...
Related Articles
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024